GWP42003

DRUG3 trials

Sponsors

Jazz Pharmaceuticals, GW Research Ltd

Conditions

Diabetes Mellitus, Type 2DyslipidemiasSchizophreniaSchizophrenia-related Psychotic DisorderUlcerative Colitis

Phase 2

GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes

CompletedNCT01217112

Jazz PharmaceuticalsDiabetes Mellitus, Type 2, Dyslipidemias

Start: 2010-10-31End: 2012-09-30Updated: 2022-10-18

A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)

CompletedNCT01562314

GW Research LtdUlcerative Colitis

Start: 2012-05-09End: 2014-08-05Updated: 2018-08-09

A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder

CompletedNCT02006628

Jazz PharmaceuticalsSchizophrenia, Schizophrenia-related Psychotic Disorder

Start: 2014-02-25End: 2015-01-08Updated: 2022-09-28

Related Papers

PTH-056 Trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis

Gut2015-06-013 citations